We are live on
!
Find out more
CASI
CASI Pharmaceuticals
CASI
CASI
Delisted
CASI was delisted on the 25th of February, 2026.
28 hedge funds and large institutions have $4.23M invested in CASI Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
75% more capital invested
Capital invested by funds: $2.41M → $4.23M (+$1.82M)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 27 → 28 (+1)
0.02% more ownership
Funds ownership: 0.38% → 0.4% (+0.02%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Holders
28
Holders Change
+1
Holders Change %
+3.7%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$83K |
| 2 |
VF
Virtu Financial
New York
|
+$47.6K |
| 3 |
HCM
Howland Capital Management
Boston,
Massachusetts
|
+$28.2K |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$14.3K |
| 5 |
Renaissance Technologies
New York
|
+$7.82K |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19K |
| 3 |
WSC
Wellington Shields & Co
New York
|
-$18.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.06K |
| 5 |
BlackRock
New York
|
-$3.64K |
